S2-E44 — The impact Of the COVID-19 Delta Variant on NAFLD and NASH

Donna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders within the Fatty Liver community.

What impact is the Delta Variant of COVD-19 having on NAFLD and NASH? Let us count the ways in this lively, fast-paced episode with Donna Cryer and the Surfers:

16:11 – Global Liver Institute’s efforts to drive priority vaccine position for transplant and severely immunocompromised liver patients

22:12 – Creating the GLI Patient Insight and Data Center

28:26 – Relevance and importance of post-vaccine immunology testing in immunocompromised liver patients

33:11 – Perspectives from comparing UK and Israel data and studying the UK experience more generally

41:51 – The importance and limits of impact from FDA’s full approval of the Pfizer-BioNTech vaccine

47:42 – Why Global vaccine equity is so important to the future of the pandemic

50:20 – How experience with COVID-19 has improved clinical trial processes and procedures

54:30 – How much will Delta and future variants slow the rate of clinical trial progress?

TOPICS: Astra Zeneca, cirrhosis, COVID-19, Diagnostic Tests, education, Global Liver Institute, NAFLD, NASH, non-invasive liver testing, Obesity, vaccines, Pfizer, BioNTech, ,Moderna, vaccine hesitancy, immunocompromised patients

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Experience Nudge Learning! Interested in a new way of learning?